How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 201–300 of 1,000
P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases
Pieper, A. A., McKnight, S. L., & Ready, J. M. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60448a · Cited by 98
Drug resistance in Giardia: Mechanisms and alternative treatments for Giardiasis
Argüello-García, R., Leitsch, D., Skinner‐Adams, T. S., & Ortega‐Pierres, M. G. (2020) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2019.11.003 · Cited by 133
Privileged scaffolds in lead generation
Zhao, H., & Dietrich, J. D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041496 · Cited by 110
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Evolving BioAssay Ontology (BAO): modularization, integration and applications
Abeyruwan, S. W., Vempati, U. D., Küçük‐McGinty, H., Visser, U., Koleti, A., Mir, A., Sakurai, K., Chung, C., Bittker, J. A., Clemons, P. A., et al. (2014) · Journal of Biomedical Semantics · doi:10.1186/2041-1480-5-s1-s5 · Cited by 102
Deep learning in image-based phenotypic drug discovery
Krentzel, D., Shorte, S. L., & Zimmer, C. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.11.011 · Cited by 114
Improving Phenotypic Measurements in High-Content Imaging Screens
Ando, D. M., McLean, C. Y., & Berndl, M. (2017) · doi:10.1101/161422 · Cited by 96
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
“Phenotypic screening can discover novel targets for cancer therapy whose specific molecular mechanism is often elucidated by future studies 15 .”
BackgroundGuzman, J. D., Evangelopoulos, D., Gupta, A., Birchall, K., Mwaigwisya, S., SAXTY, B. A., McHugh, T. D., Gibbons, S., Malkinson, J. P., & Bhakta, S. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002672 · Cited by 95
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
Dunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
“Converting the indole into a benzimidazole (22), pyrrole (23), or carbazole (24) had a minimal effect on the ability of these molecules to promote neuronal growth.”
BackgroundSams‐Dodd, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.010 · Cited by 97
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
“Phenotypic discovery has been shown to be a reliable method for the discovery and development of first- in-class drugs 65 and is arguably more effective than target-based drug discovery in identifying compounds that succeed in clinical development 66,67 .”
MethodMachine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
Ekins, S., Lage de Siqueira-Neto, J., McCall, L.-I., Sarker, M., Yadav, M., Ponder, E. L., Kallel, E. A., Kellar, D., Chen, S., Arkin, M., et al. (2015) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0003878 · Cited by 93
Plasmodium Kinases As Targets For New-Generation Antimalarials
Lucet, I. S., Tobin, A. B., Drewry, D. H., Wilks, A. F., & Doerig, C. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.183 · Cited by 93
Filtering promiscuous compounds in early drug discovery: is it a good idea?
Senger, M. R., Fraga, C. A. M., Dantas, R. F., & Silva, F. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.004 · Cited by 95
Nagaraj, A. B., Wang, Q. Q., Joseph, P., Zheng, C., Chen, Y., Kovalenko, O., Singh, S., Armstrong, A., Resnick, K., Zanotti, K., et al. (2018) · Oncogene · doi:10.1038/onc.2017.328 · Cited by 93
Gurgis, F., Ziaziaris, W. A., & Munoz, L. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.090365 · Cited by 99
Cell-Based Assay Design for High-Content Screening of Drug Candidates
Nierode, G. J., Kwon, P. S., Dordick, J. S., & Kwon, S. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1508.08007 · Cited by 108
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 99
Overcome Cancer Cell Drug Resistance Using Natural Products
Wang, P., Yang, H., Yang, Y. J., Wang, L., & Lee, S. C. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/767136 · Cited by 91
Schulze, C. J., Bray, W. M., Woerhmann, M. H., Stuart, J., Lokey, R. S., & Linington, R. G. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.007 · Cited by 91
Ionophoric effects of the antitubercular drug bedaquiline
Hards, K., McMillan, D. G. G., Schurig-Briccio, L. A., Gennis, R. B., Lill, H., Bald, D., & Cook, G. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803723115 · Cited by 95
Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases
Aulner, N., Danckaert, A., Ihm, J., Shum, D., & Shorte, S. L. (2019) · Trends in Parasitology · doi:10.1016/j.pt.2019.05.004 · Cited by 102
CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma
Ross, N. T., Lohmann, F., Carbonneau, S., Fazal, A., Weihofen, W. A., Gleim, S., Salcius, M., Sigoillot, F., Henault, M., Carl, S. H., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0424-1 · Cited by 91
Systems biology in drug discovery and development
Berg, E. L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.003 · Cited by 104
The compromise of virtual screening and its impact on drug discovery
Slater, O., & Kontoyianni, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1604677 · Cited by 92
Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics
Imig, J. D. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.015 · Cited by 93
Traditional Chinese Medicine and Clinical Pharmacology
Marshall, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_60 · Cited by 139
Bioinformatics and variability in drug response: a protein structural perspective
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., & Altman, R. B. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0843 · Cited by 89
Phenotypic screening, take two
Kotz, J. (2012) · Science-Business eXchange · doi:10.1038/scibx.2012.380 · Cited by 86
Controlling Differentiation of Stem Cells for Developing Personalized Organ‐on‐Chip Platforms
Geraili, A., Jafari, P., Hassani, M. S., Araghi, B. H., Mohammadi, M. H., Ghafari, A. M., Tamrin, S. H., Modarres, H. P., Kolahchi, A. R., Ahadian, S., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700426 · Cited by 88
Pasrija, P., Jha, P. K., Upadhyaya, P., Khan, M. S., & Chopra, M. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220701091339 · Cited by 111
Expanding medicinal chemistry space
Barker, A. J., Kettle, J. G., Nowak, T., & Pease, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.008 · Cited by 104
Gittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.01.007 · Cited by 87
Computational Drug Repurposing: Current Trends
Karaman, B., & Sippl, W. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530100332 · Cited by 95
Dhiman, N., Kingshott, P., Sümer, H., Sharma, C. S., & Rath, S. N. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.02.070 · Cited by 90
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery
Li, H., Zhou, H., Wang, D., Qiu, J., Zhou, Y., Li, X., Rosenfeld, M. G., Ding, S., & Fu, X.-D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200305109 · Cited by 86
Activity-Based DNA-Encoded Library Screening
Cochrane, W. G., Malone, M. L., Dang, V. Q., Cavett, V. J., Satz, A. L., & Paegel, B. M. (2019) · ACS Combinatorial Science · doi:10.1021/acscombsci.9b00037 · Cited by 85
Sundaramurthy, V., Barsacchi, R., Samusik, N., Marsico, G., Gilleron, J., Kalaidzidis, I. V., Meyenhofer, F., Bickle, M., Kalaidzidis, Y. L., & Zerial, M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.01.008 · Cited by 95
Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery
Davis, R. L. (2020) · iScience · doi:10.1016/j.isci.2020.101487 · Cited by 97
Diversity-oriented synthesis as a tool for identifying new modulators of mitosis
Ibbeson, B. M., Laraia, L., Alza, E., Connor, C. J. O., Tan, Y. S., Davies, H. M. L., McKenzie, G. J., Venkitaraman, A. R., & Spring, D. R. (2014) · Nature Communications · doi:10.1038/ncomms4155 · Cited by 86
Challenges and Opportunities in Central Nervous System Drug Discovery
Danon, J. J., Reekie, T. A., & Kassiou, M. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.04.009 · Cited by 89
Why and how have drug discovery strategies in pharma changed? What are the new mindsets?
Mignani, S., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J.-P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.007 · Cited by 82
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 87
Use of artificial intelligence to enhance phenotypic drug discovery
Malandraki-Miller, S., & Riley, P. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.013 · Cited by 97
Shah, A. M., Myhre, P. L., Arthur, V., Dorbala, P., Rasheed, H., Buckley, L. F., Claggett, B. L., Liu, G., Ma, J., Nguyen, N. Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44680-3 · Cited by 100
Haston, K. M., & Finkbeiner, S. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103548 · Cited by 82
High-throughput analysis of behavior for drug discovery
Alexandrov, V., Brunner, D., Hanania, T., & Leahy, E. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.047 · Cited by 81
Andrade, E., Bento, A. F., Cavalli, J., de Oliveira, S. K. F., Freitas, C. S., Marcon, R., Schwanke, R. C., Siqueira, J. M., & Calixto, J. Β. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165644 · Cited by 99
Paciaroni, N. G., Ratnayake, R., Matthews, J., Norwood, V. M., Arnold, A. C., Dang, L. H., Luesch, H., & Huigens, R. W. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604795 · Cited by 81
Drug Discovery in Fish, Flies, and Worms
Strange, K. B. (2016) · ILAR Journal · doi:10.1093/ilar/ilw034 · Cited by 82
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Application of Biocatalysis to on‐DNA Carbohydrate Library Synthesis
Thomas, B., Lu, X., Birmingham, W. R., Huang, K., Both, P., Reyes-Martínez, J. E., Young, R. J., Davie, C. P., & Flitsch, S. L. (2017) · ChemBioChem · doi:10.1002/cbic.201600678 · Cited by 80
Loryan, I., Sinha, V., Mackie, C. E., Peer, A. V., Drinkenburg, W. H. I. M., Vermeulen, A., Morrison, D., Monshouwer, M., Heald, D., & Hammarlund‐Udenaes, M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1319-1 · Cited by 85
The role and application of bioinformatics techniques and tools in drug discovery
Zhang, S., Liu, K., Liu, Y., Hu, X., & Gu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1547131 · Cited by 110
Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites
Merritt, C., Silva, L. E., Tanner, A. L., Stuart, K. D., & Pollastri, M. P. (2014) · Chemical Reviews · doi:10.1021/cr500197d · Cited by 82
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
Drug repositioning of herbal compounds via a machine-learning approach
Kim, E., Choi, A.-S., & Nam, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2811-8 · Cited by 91
Buckingham, S. D., Partridge, F. A., & Sattelle, D. B. (2014) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.10.004 · Cited by 83
Affinity-based target identification for bioactive small molecules
Kawatani, M., & Osada, H. (2013) · MedChemComm · doi:10.1039/c3md00276d · Cited by 92
Sherman, S. P., & Bang, A. G. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031906 · Cited by 84
Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches
Kubota, K., Funabashi, M., & Ogura, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.08.002 · Cited by 88
Computer vision meets microfluidics: a label-free method for high-throughput cell analysis
Zhou, S., Chen, B., Fu, E. S., & Yan, H. G. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00562-8 · Cited by 86
Höing, S., Rudhard, Y., Reinhardt, P., Glatza, M., Stehling, M., Wu, G., Peiker, C., Böcker, A., Parga, J. A., Bunk, E. C., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.005 · Cited by 84
Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 84
Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints
Reisen, F., Sauty de Chalon, A., Pfeifer, M., Zhang, X., Gabriel, D., & Selzer, P. (2015) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2015.656 · Cited by 76
Matheny, C. J., Wei, M. C., Bassik, M. C., Donnelly, A. J., Kampmann, M., Iwasaki, M., Piloto, O., Solow-Cordero, D. E., Bouley, D. M., Rau, R., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.014 · Cited by 74
Cheng, T., Li, Q., Wang, Y., & Bryant, S. H. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200192v · Cited by 85
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Belema, M., Lopez, O. D., Bender, J. A., Romine, J. L., Laurent, D. R. S., Langley, D. R., Lemm, J. A., O’Boyle, D. R., Sun, J.-H., Wang, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401793m · Cited by 75
Duarte, Y., Márquez‐Miranda, V., Miossec, M. J., & González-Nilo, F. D. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1554 · Cited by 90
Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
Kumar, R., Harilal, S., Gupta, S. V., Jose, J., Parambi, D. G. T., Uddin, M. S., Shah, M. A., & Mathew, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111602 · Cited by 79
The problem of genotype and sex differences in life expectancy in transgenic AD mice
Rae, E. A., & Brown, R. E. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.002 · Cited by 89
Montagnani Marelli, M., Marzagalli, M., Moretti, R. M., Beretta, G., Casati, L., Comitato, R., Gravina, G. L., Festuccia, C., & Limonta, P. (2016) · Scientific Reports · doi:10.1038/srep30502 · Cited by 74
Analysis of live cell images: Methods, tools and opportunities
Nketia, T. A., Sailem, H., Rohde, G. K., Machiraju, R., & Rittscher, J. (2017) · Methods · doi:10.1016/j.ymeth.2017.02.007 · Cited by 78
Wu, S., Li, Y., Xu, G., Chen, S., Zhang, Y., Liu, N., Dong, G., Miao, C., Su, H., Zhang, W., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.039 · Cited by 74
Watson, P. M. D., Kavanagh, E., Allenby, G., & Vassey, M. (2017) · SLAS Discovery · doi:10.1177/2472555217691450 · Cited by 74
Peón, A., Naulaerts, S., & Ballester, P. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-04264-w · Cited by 74
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 73
Grist, S. M., Nasseri, S. S., Laplatine, L., Schmok, J. C., Yao, D. R., Hua, J., Chrostowski, L., & Cheung, K. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-54001-8 · Cited by 79
Target identification of small molecules based on chemical biology approaches
Futamura, Y., Muroi, M., & Osada, H. (2013) · Molecular BioSystems · doi:10.1039/c2mb25468a · Cited by 82
Ogbourne, S. M., & Parsons, P. G. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.07.002 · Cited by 80
Functional genomics to uncover drug mechanism of action
Nijman, S. M. B. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1963 · Cited by 78
Kakeya, H. (2016) · Natural Product Reports · doi:10.1039/c5np00120j · Cited by 73
Recent advances in phenotypic drug discovery
Swinney, D. C., & Lee, J. A. (2020) · F1000Research · doi:10.12688/f1000research.25813.1 · Cited by 72
Self-citationThe Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance
Selen, A., Dickinson, P. A., Müllertz, A., Crison, J. R., Mistry, H. B., Cruañes, M. T., Martinez, M. N., Lennernäs, H., Wigal, T. L., Swinney, D. C., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24162 · Cited by 75
Self-citationHistamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination
Chen, Y., Zhen, W., Guo, T., Zhao, Y., Liu, A., Rubio, J. P., Krull, D., Richardson, J. C., Lu, H., & Wang, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189380 · Cited by 71
Large‐scale image‐based screening and profiling of cellular phenotypes
Bougen‐Zhukov, N., Loh, S. Y., Lee, H. K., & Loo, L. (2017) · Cytometry Part A · doi:10.1002/cyto.a.22909 · Cited by 73
Engineering Xenopus embryos for phenotypic drug discovery screening
Schmitt, S. M., Gull, M., & Brändli, A. W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.004 · Cited by 86
Recruitment of Brown Adipose Tissue as a Therapy for Obesity-Associated Diseases
Boss, O., & Farmer, S. R. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00014 · Cited by 71
Liang, Z., Currais, A. J. M., Soriano‐Castell, D., Schubert, D. A., & Maher, P. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107749 · Cited by 77
Connecting chemistry and biology through molecular descriptors
Fernández-Torras, A., Comajuncosa-Creus, A., Duran-Frigola, M., & Aloy, P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.09.001 · Cited by 68
Toward stem cell-based phenotypic screens for neurodegenerative diseases
Khurana, V., Tardiff, D. F., Chung, C. Y., & Lindquist, S. L. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.79 · Cited by 78
How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice
Haasen, D., Schopfer, U., Antczak, C., Guy, C. T., Fuchs, F., & Selzer, P. M. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2017.796 · Cited by 81
Predicting protein targets for drug-like compounds using transcriptomics
Pabon, N. A., Xia, Y., Estabrooks, S. K., Ye, Z., Herbrand, A. K., Süß, E., Biondi, R. M., Assimon, V. A., Gestwicki, J. E., Brodsky, J. L., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006651 · Cited by 79
The future of phenotypic drug discovery
Berg, E. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.010 · Cited by 81
Pacico, N., & Mingorance, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084755 · Cited by 69
Schulz, M. M. P., Reisen, F., Zgraggen, S., Fischer, S., Yuen, D., Kang, G. J., Chen, L., Schneider, G., & Detmar, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206036109 · Cited by 69
Park, J., Oh, S., & Park, S. B. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200609 · Cited by 75
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
Wooden, B., Goossens, N., Hoshida, Y., & Friedman, S. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.065 · Cited by 69
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.